Scandinavia

#Financing #Immunotherapy #Oncology #Ovarian cancer #Scandinavia

TILT Biotherapeutics closes $25 million Series B financing

Finnish biotechnology company TILT Biotherapeutics (Tiltbio) has raised $25.6 million (€22.6 million) in a Series B financing.  The financing will support a Phase II clinical trial of Tiltbio’s lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase Ib trial in melanoma in combination with TILs and other… Read More

#Business & Investment #News

#GLP-1 #Market reporting #Novo Nordisk #Obesity #Scandinavia #Weight loss

What effect have weight loss drugs had on the Scandinavian economy?

In less than a decade GLP-1 receptor agonists have transformed the treatment of obesity and made Novo Nordisk Europe’s most valuable company. Diana Spencer explores the current impact and potential future for these drugs. Originally designed in Scandinavia as a maintenance therapy for type 2 diabetes, GLP-1 receptor agonists are… Read More

#Exclusive Content #Market Reports #Trends & Analysis

Drug discovery innovation
#AAV #Cell and gene therapy #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Immunology / Virology & Vaccines #Interview #Life sciences #Market reporting #Precision medicine #RNA #RNA sequencing #Scandinavia #Sweden #Transcriptomics

Podcast: Innovation drivers and opportunities for drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovation drivers and opportunities for drug discovery”, which covers three articles written Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Optimising AAV capsid purification through improved analytics How… Read More

#News

Women in Life Science Denmark
#Denmark #Diversity #Gender equality #Life sciences #Novo Nordisk #Scandinavia

Danish women’s network promotes diversity in life sciences

A science-centric network for women in senior positions across industry and academia has launched in Denmark to strengthen the life sciences industry and promote talent, diversity and inclusiveness.   Women in Life Science Denmark (WiLD) has received support from the Novo Nordisk Foundation, contributing €56,000 ($60,293) over the… Read More

#News

Scandinavia
#Drug development #Drug discovery #Life sciences #Market reporting #Scandinavia #Sweden

Scandinavia: insight into opportunities for drug discovery

DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. Scandinavia represents one of the most exciting but perhaps underrepresented markets for the discovery and development of pharmaceuticals. Though not without its challenges, the life sciences industry in Scandinavia… Read More

#Exclusive Content #Market Reports